New pill hopes to tackle Hard-to-Treat lung cancer
NCT ID NCT07117890
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations and has not been treated before. The goal is to see if the drug can shrink tumors and how safe it is. Participants take either 200mg or 300mg of the drug once daily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sunvozertinib (a targeted cancer pill)
- What this could lead to
- If successful, this could provide a new oral treatment option for people with advanced lung cancer that has certain rare EGFR mutations.
- What could go wrong
- This is a small, early-phase study with only 34 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?